| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_881cd61f757ee9a250383b1594a91534
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d025f648027e166f146610e4520f221c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f28817fba3808a82ab9e7d65a33d02b6 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-90694 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-49
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5308
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M5-168
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y107-03003
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-96
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-44 |
| filingDate |
2010-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1fe65738855f6c5ae97b64075f7a919
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e2bf9ede5699c75d13ce88253551fb12 |
| publicationDate |
2012-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2012301454-A1 |
| titleOfInvention |
Methods and Kits for Predicting Infusion Reaction Risk and Antibody-Mediated Loss of Response by Monitoring Serum Uric Acid During Pegylated Uricase Therapy |
| abstract |
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11598767-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10160958-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10823727-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020160324-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10139399-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10731139-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11639927-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11345899-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020160325-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11781119-B2 |
| priorityDate |
2009-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |